In a recent development, Novo Nordisk has submitted a marketing application to the U.S. Food and Drug Administration for an oral version of its weight-loss drug Wegovy. The FDA is expected to make a decision on the application by the fourth quarter of this year.
If approved, Novo Nordisk's innovative once-daily oral GLP-1 drug will mark a significant advancement in chronic weight management treatments, becoming the first of its kind in this category. This oral version will provide a convenient and accessible option for individuals seeking to address weight management issues.
Currently, Novo Nordisk's oral GLP-1 drug Rybelsus, which shares the same active ingredient semaglutide as Wegovy, is already approved for managing blood sugar levels in adults with diabetes. With the success of Rybelsus, Novo Nordisk is poised to further expand its portfolio with Wegovy as another promising option in the realm of weight management pharmaceuticals.
The potential approval of Wegovy as an oral GLP-1 drug signifies a positive step towards addressing the global health challenge of obesity and supports Novo Nordisk's commitment to providing innovative solutions for the well-being of individuals.